This NHMRC is a beginner and learning on the job. Its Project Team Report explained in their 2025 Scope Survey: one lesson is how to get more uptake-intake (reply), if not through medical Colleges.
* more replies from more of those who don’t use 8-page profiling Tools:
- eg did not use DePaul’s PEM Tool
- eg did not use Australia’s NHMRC Practitioner Guideline Survey Tool (NHMRC Team’s 8th page was only for permission to publish)
* and more replies from more of the professional stakeholders:
- around 40 replied that they mostly do want a !!
factsheet !! and summary
* and more replies from more patient stakeholders being reconditioned by the 3 correlated conditions:
- Long Covid with pride of place
- then O.I “also known as POTS, so aka POTS (Orthostatic Intolerance)”
- then Fibromyalgia being such old hat it got left behind to trail in behind, but was it not the first known associate?
The NHMRC Project Team regarding other conditions amongst the 1087 replies said:
- 35 Long Covid
- 13 POTS
- 3 Fibromyalgia
- some of these respondents had more than one condition.
- 3 people reported that they had similar conditions but did not identify what those conditions were.
This NHMRC Project Team said:
The survey was open to the public and was designed to gather insights from individuals with ME/CFS and related conditions (Long Covid, postural orthostatic intolerance syndrome (POTS) and fibromyalgia), carers, GPs and other healthcare professionals that provide care to people with ME / CFS and related conditions.
Does this mean Australia still has no stand-alone Practitioner Guidelines on Fibromyalgia, O.I, or Long Covid, not even in the pipeline? If none, then is this because these conditions are also “under-represented” or “dismissed”?
Why do some say O.I is now a symptom of M.E, but others say its co-morbid, a known associate? If O.I is a symptom then is that a core symptom except for any outliers, or a considerable subgroup? Why say it causes cerebral hypo-perfusion, when others say its caused by cerebral hypo-perfusion? Is cerebral hypo-perfusion co-morbid or a proven, or indicated, or accepted symptom, or subgroup?
How is the Council supposed to collate opinion, experience, literature and proof, on such an eternally fluid profile always masked and up for grabs? With an engagement problem to start with? So do we have available professional and patient experts to explain what they reckon might be the problem(s) causing such a tiny response from all except 915 Patients (16 patients with a dual role)
Only 61 Carers, only 9 Kith and Kin. Only 62 Clinicians, 22 with a dual role. Only 14 Researchers, 4 with a dual role, 3 unspecified, 11 researching occupational therapy, autonomic dysfunction, molecular and cell biology, immunological disturbances, gut health and exercise physiology. Also 10 odd-bods with no role to mention. But surely Australia can muster more than 1087 replies.
How might this compare with the initial scoping response to a NICE Guideline? What gives? So many possible reasons for not reaching - or not engaging - the different professional cohorts, and the different patient cohorts, at the scales involved. Is this an Australia thing about surveys, or an 8-page thing, or a wheelspin in the questionnaire, an NHMRC shortfall, or a professional shortfall?
Obviously it is professionals who need the most help to enter data on a survey. Patients too, but for each professional reply there were 18 patient replies (I’m not AI, nor AI-assisted, but I too may err).
The devil is in the detail. So people tend to tune out devilish detail and of course this got automated.
I observe that sedentary professionals are conditioned to enter data on automated software tools all day sending pre-formatted tasks into the loop of workstations. No-one takes more than 3 minutes to enter one task, at most 5 minutes, hence the total illiteracy for further reading and writing which we encounter and cannot yet counter. Computers rely on clients to repeat detail at each node in the loop